Compared with patients without cGVHD, the percentage of CD19+CD21low B cells, as well as B cell-activating factor (BAFF) levels and the BAFF/CD19+ ratio, are notably elevated in patients with newly diagnosed BOS. This evidence concerns the gene CD19 and Buschke-Ollendorff syndrome.